Reduction in bilateral Nasal Polyp score as early as Week 4, sustained through Week 521

  • Week 4 (SINUS-52): 18% improvement in NPS with DUPIXENT vs 1% worsening with placebo1,a
  • Week 24 (SINUS-24): 27% improvement in NPS with DUPIXENT (pooled arms) vs 4% worsening with placebo; LSM difference vs placebo -1.80 (95% CI: -2.10, -1.51) (coprimary endpoint)1,c
  • Week 52 (SINUS-52): 39% improvement in NPS with DUPIXENT vs 4% worsening with placebo1,d
Sustained polyp burden reduction with DUPIXENT 300 mg Q2W (SINUS-52)1,d

Illustrations of endoscopy adapted from actual patient images. Individual results may vary.

  • Week 24 (SINUS-24): -1.89 improvement in NPS with DUPIXENT vs 0.17 worsening with placebo (coprimary endpoint)2,e

aWeek 4 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) vs placebo + INCS (n=153): -1.18 (95% CI: -1.47, -0.90) (-1.13 from a baseline score of 6.07 vs 0.05 from a baseline score of 5.96, respectively) (P<0.0001).1

bAt Week 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) vs placebo + INCS (n=153): -1.79 (95% CI: -2.13, -1.44) (-1.69 from a baseline score of 6.07 vs. 0.09 from a baseline score of 5.96, respectively) (P<0.0001).1

cAt Week 24 in SINUS-52 (co-primary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) vs placebo + INCS (n=153): -1.80 (95% CI: -2.10, -1.51) (-1.69 from a baseline score of 6.18 vs 0.10 from a baseline score of 5.96, respectively) (P<0.0001).1

dWeek 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) vs placebo + INCS (n=153): -2.40 (95% CI: -2.77, -2.02) (-2.24 from a baseline score of 6.07 vs 0.15 from a baseline score of 5.96, respectively) (P<0.0001).1

eWeek 24 in SINUS-24 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=143) vs placebo + INCS (n=133): -2.06 (95% CI: -2.43, -1.69) (-1.89 from a baseline score of 5.64 vs 0.17 from a baseline score of 5.86, respectively).2

Nasal polyp score (NPS), the sum of right and left nostril scores (range 0 to 4 for each nostril, range 0 to 8 in total) as evaluated by nasal endoscopy: reduced score indicates improvement.2

CI, confidence interval; INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

see snot-22 results

Back to lmk-ct results

Explore the Safety Data
and Study Designs

View Safety Data SEE THE FULL STUDY DESIGNS

Dosage and
Administration
See the recommended dosing and
administration options for patients
on DUPIXENT.
EXPLORE ADMINISTRATION OPTIONS